In:
Antiviral Therapy, SAGE Publications, Vol. 10, No. 2 ( 2005-02), p. 285-300
Kurzfassung:
The safety and immunogenicity of an HIV-1 nef-expressing modified vaccinia virus Ankara (MVA) was investigated in 14 HIV-1-positive patients (CD4 〉 400/μl) on highly active antiretroviral therapy (HAART). Patients were vaccinated at weeks 0, 4 and 16, followed by interruption of HAART at week 18. MVA- nef was well-tolerated except for local reactions, with only mild systemic side effects reported in a few patients. Vaccination with MVA- nef was associated with recognition of new HIV-1 T-cell epitopes (cytotoxic T-lymphocyte epitopes in 9/14 patients, CD4 epitope/recombinant Nef protein in 2/14) and an increase in CD4+ and CD8+ T cells. All patients had been vaccinated against smallpox and a strong T-cell and antibody response to MVA was induced in all patients. After interruption of HAART, viral load rebounded in all patients, but after a median time of 36 (4–76) weeks in 9/14 patients, viraemia remained below the pre-HAART viral load and CD4 counts stayed above the pre-HAART levels. While six patients have remained off therapy for a median time of 64 (57–76) weeks, HAART was resumed in 8/14 patients after a median treatment interruption time of 15 (4–38) weeks. This study has demonstrated that MVA- nef is safe and immunogenic in HIV-1-infected subjects and has provided encouraging data on the potential of therapeutic vaccinations.
Materialart:
Online-Ressource
ISSN:
1359-6535
,
2040-2058
DOI:
10.1177/135965350501000212
Sprache:
Englisch
Verlag:
SAGE Publications
Publikationsdatum:
2005
ZDB Id:
2118396-X
SSG:
15,3
